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Abstract
Background: Primary intestinal non-Hodgkin lymphoma (NHL) is a heterogeneous disease with regard to anatomic
and histologic distribution. Thus, analyses focusing on primary intestinal NHL with large number of patients are
warranted.
Methods: We retrospectively analyzed 581 patients from 16 hospitals in Korea for primary intestinal NHL in this
retrospective analysis. We compared clinical features and treatment outcomes according to the anatomic site of
involvement and histologic subtypes.
Results: B-cell lymphoma (n = 504, 86.7%) was more frequent than T-cell lymphoma (n = 77, 13.3%). Diffuse large
B-cell lymphoma (DLBCL) was the most common subtype (n = 386, 66.4%), and extranodal marginal zone B-cell
lymphoma of mucosa-associated lymphoid tissue (MALT) was the second most common subtype (n = 61, 10.5%).
B-cell lymphoma mainly presented as localized disease (Lugano stage I/II) while T-cell lymphomas involved
multiple intestinal sites. Thus, T-cell lymphoma had more unfavourable characteristics such as advanced stage at
diagnosis, and the 5-year overall survival (OS) rate was significantly lower than B-cell lymphoma (28% versus 71%, P
< 0.001). B symptoms were relatively uncommon (20.7%), and bone marrow invasion was a rare event (7.4%). The
ileocecal region was the most commonly involved site (39.8%), followed by the small (27.9%) and large intestines
(21.5%). Patients underwent surgery showed better OS than patients did not (5-year OS rate 77% versus 57%, P <
0.001). However, this beneficial effect of surgery was only statistically significant in patients with B-cell lymphomas
(P < 0.001) not in T-cell lymphomas (P = 0.460). The comparison of survival based on the anatomic site of
involvement showed that ileocecal regions had a better 5-year overall survival rate (72%) than other sites in
consistent with that ileocecal region had higher proportion of patients with DLBCL who underwent surgery. Age >
60 years, performance status ≥ 2, elevated serum lactate dehydrogenase, Lugano stage IV, presence of B
symptoms, and T-cell phenotype were independent prognostic factors for survival.
Conclusions: The survival of patients with ileocecal region involvement was better than that of patients with
involvement at other sites, which might be related to histologic distribution, the proportion of tumor stage, and
need for surgical resection.
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The gastrointestinal tract is the most commonly involved
extranodal location of non-Hodgkin lymphoma (NHL)
[1,2]. The intestines are the second most common site of
involvement following the stomach, and account for 30
to 40% of primary gastrointestinal lymphomas [1-3].
However, information regarding primary intestinal NHL
is relatively scarce because the majority of previous stu-
dies focused on gastric lymphoma [1,3,4]. The limited
number of studies about primary intestinal NHL analyzed
relatively small numbers of patients [5-12]. Another pro-
blem is that the classification of the pathology differs
depending on the study period, as the majority of studies
were retrospective analyses [1,4-6,9,13-15]. The use of
old histologic classifications, such as the Kiel classifica-
tion, makes comparisons among reported results difficult
[1,5,6,9,11].
The ambiguity of anatomic classification is another
obstacle to the analysis of primary intestinal NHL. Dis-
eases involving the intestines are dichotomized into small
and large intestinal diseases depending on the affected
anatomic site. However, primary intestinal NHL most
commonly involves the ileocecal region, probably due to
the high proportion of lymphoid tissue [4,6,16]. Because
the ileocecal region includes the area from the distal ileum
to the cecum, it is often difficult to designate the ileocecal
region as part of the small or large intestine. Thus, the
designation for this region differs among studies, as some
considered it part of the small or large intestine [1,9,10],
and others distinguished it from the small and large intes-
tine entirely [4,17]. Therefore, the estimated incidence
rates of small and large intestinal lymphoma also varied
among studies [4,17].
Due to this heterogeneity with regard to anatomic and
histologic distribution of primary intestinal NHL, studies
focusing on primary intestinal NHL in large patient sam-
ples using current pathologic classifications are warranted
to understand this disease entity. Therefore, we analyzed
data from Korean patients with primary intestinal NHL in
the present multicenter retrospective study. We distin-
guished the ileocecal regionf r o mt h es m a l la n dl a r g e
intestine for the purposes of classification. We analyzed
the histologic distribution of primary intestinal NHL, and
compared the clinical features and survival outcomes of
patients.
Methods
Patients and tumor localization
Patients who presented with predominant intestinal
lesions were defined as primary intestinal NHL accord-
ing to the definition for primary gastrointestinal tract
lymphoma proposed in previous reports [18,19]. Patho-
logical diagnoses were made according to the Revised
European-American Lymphoma (REAL) classification or
the World Health Organization (WHO) classification
depending on the time of diagnosis. Cases with ambigu-
ous histologic diagnosis or insufficient data regarding
the pathology were excluded from this analysis. Tumor
locations were determined using imaging findings, such
as computerized tomography (CT), or surgical findings
if surgical resection was performed. Small intestinal lym-
phomas were considered to be lymphomas between the
duodenum and the ileum, while large intestinal lympho-
mas were considered to be lymphomas between the
ascending colon and the rectum. The ileocecal region
was defined as the area between the distal ileum to the
cecum.
Clinical data
Investigators affiliated with the Consortium for Improv-
ing Survival of Lymphoma (CISL) reviewed medical
records and gathered clinical data for patients diagnosed
with primary intestinal NHL between 1993 and 2010.
Data included patient demographics and clinical features
at diagnosis including stage, Eastern Cooperative Oncol-
ogy Group (ECOG) performance status, serum lactate
dehydrogenase (LDH), international prognostic index
(IPI), histologic subtypes, the presence of B symptoms,
and tumor location. Not all patients underwent colono-
scopy for diagnosis because substantial number of
patients underwent surgery to remove primary mass as
diagnostic and therapeutic purpose. Thus, the specimen
for pathologic diagnosis was obtained from biopsy under
colonoscopy or surgically removed primary mass. Few
patients underwent other specialized diagnostic techni-
ques such as capsule endoscopy and double balloon
endoscopy. All patients underwent imaging studies for
staging work-up, including chest and abdomen-pelvis CT
scans. The results of positron emission tomography
(PET)/CT scan were not included in this study because a
limited number of patients underwent PET/CT scan for
their staging work-up. Patients were staged according to
the Lugano staging system for gastrointestinal lympho-
mas as previously reported [20,21]. Stage I is defined as
disease confined to the intestine, stage II is defined as
disease extending to local (II-1) or distant (II-2) nodes,
stage II-E is defined as disease involving adjacent organs
or tissues, and stage IV is defined as disseminated extra-
nodal involvement or concomitant supradiaphragmatic
lymph node involvement. The IPI risk was calculated
from five parameters including age, performance status,
serum LDH, number of extranodal involvement and
Lugano stage. Clinical manifestation related with intest-
inal lesions such as intestinal obstruction, bleeding and
perforation were analyzed because other symptoms were
not specific to intestinal lesions. Data regarding treat-
ments and outcomes include type of primary treatment,
treatment response, and survival status. Response was
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review board of each participating center approved this
retrospective analysis, which was a part of the larger
C I S Ls t u d yr e g i s t e r e da th t t p : / / w w w . c l i n i c a l t r i a l s . g o v
(#NCT01043302).
Statistical analysis
The Fisher’s exact test was applied to assess the associa-
tion between categorical variables, and the Kruskal-Wallis
test was used to compare mean values. Overall survival
(OS) was calculated from the date of diagnosis to the date
of the final follow-up or death from any cause. Progres-
sion-free survival (PFS) was calculated from the date of
diagnosis to the date of disease progression, relapse, or
death from any cause. Survival was estimated using
Kaplan-Meier curves and compared by the log-rank test.
The Cox proportional hazard regression model was used
in multivariate analyses to identify prognostic factors.
Two-sided P values < 0.05 were considered significant.
Results
Primary site of involvement
We enrolled 581 patients from 16 hospitals in Korea for
primary intestinal NHL in this retrospective analysis. 361
patients (62.1%) underwent colonoscopy for diagnostic
purpose while 220 patients were diagnosed after surgery.
Among patients undergoing colonoscopy, 334 patients
were pathologically diagnosed as NHL whereas 27 patients
were not diagnosed by colonoscopic biopsy. These 27
patients were diagnosed after surgical resection of primary
intestinal mass. The majority of patients involved had sin-
gle lesions in the intestines (89.2%). The ileocecal region
was the most commonly involved site (n = 231, 39.8%,
Table 1). Multiple intestinal involvement cases included
the combined involvement of small and large intestines,
and the involvement of two or more lesions within the
small or large intestines (n = 63, 10.8%). Multiple intestinal
involvements was significantly more frequent in T-cell
lymphoma. The jejunal involvement was also more com-
mon in T-cell than B-cell lymphomas (15.6% versus 4.4%),
thus, T-cell lymphomas showed more frequent involve-
ment of the small intestine (P = 0.02). B-cell lymphomas
accounted for the majority of ileocecal region lymphoma
(n = 221, 95.7%).
Characteristics of patients
The median age of the patients was 56 years (range: 15-92
years), and the male to female ratio was 1.71:1. Most
patients had good performance status (≤ ECOG grade 0/1,
84.3%) and localized disease (Lugano stage I/II 71.1%).
Thus, the IPI risks in our patients were mainly low or low
intermediate (75.4%). B symptoms were relatively uncom-
mon (20.7%), and bone marrow invasion was a rare event
in primary intestinal NHL (7.4%, Table 2). Clinical presen-
tations associated with intestinal obstruction such as intus-
susceptions were found in 96 patients (16.5%), and all
these patients underwent emergent surgery. The frequency
of bleeding (n = 13, 2.2%) and perforation (n = 25, 4.3%)
was relatively lower than obstruction. Among the cases
with perforation, 10 cases occurred during chemotherapy.
When the characteristics of patients were compared
according to the primary site of involvement, there were
no significant differences. Only patients with multiple
intestinal involvements were more likely to show high or
high-intermediate IPI risk (Table 2).
Histological distribution
Diffuse large B-cell lymphoma (DLBCL) was the most
common subtype (n = 386, 66.4%), and extranodal mar-
ginal zone B- cell lymphoma of mucosa-associated lym-
phoid tissue (MALT) was the second most common
subtype (n = 61, 10.5%). Burkitt lymphoma (BL, n = 31,
5.3%), mantle cell lymphoma (MCL, n = 19, 3.3%) and
follicular lymphoma (FL, n = 7, 1.2%) together com-
prised only a minor fraction of intestinal NHL cases.
The proportion of T-cell lymphomas was relatively
Table 1 Anatomic distribution of primary intestinal NHL
Primary site Total cases
(n = 581)
B-cell lymphoma
(n = 504)
T-cell lymphoma
(n = 77)
P value*
Small intestine
Duodenum 31 (5.3) 25 (5.0) 6 (7.8) 0.02
Jejunum 34 (5.9) 22 (4.4) 12 (15.6)
Ileum 97 (16.7) 84 (16.7) 13 (16.9)
Ileocecal region 231 (39.8) 221 (43.8) 10 (13.0) < 0.001
Large intestine
Ascending/transverse colon 87 (15.0) 70 (13.9) 17 (22.1) 0.14
Descending/sigmoid colon 12 (2.1) 11 (2.2) 1 (1.3)
Rectum 26 (4.5) 25 (5.0) 1 (1.3)
Multiple intestinal Involvement 63 (10.8) 46 (9.1) 17 (22.1) 0.002
NA: not applicable
*Fisher’s exact test was used to assess the association between immunophenotype and the primary site in small and large intestine.
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eral T-cell lymphoma, unspecified (PTCL-U, n = 34,
5.9%), enteropathy-associated T-cell lymphoma (EATL,
n = 25, 4.3%) and extranodal NK/T cell lymphoma
(ENKTL, n = 18, 3.1%).
Comparison of histologic subtypes
The median age of MCL (60 years, Table 3) was the high-
est while BL, PTCL-U, and ENKTL had younger median
ages (P = 0.002, Table 3). The majority of DLBCL and
MALT cases presented as localized disease, while other
subtypes more frequently presented as Lugano stage IV.
The proportion of high/high-intermediate IPI risk
patients was greater in the group with BL (Table 3).
T-cell lymphoma showed more frequent occurrence of B
symptoms (> 35%). The ileocecal region was the most
common primary site of involvement in DLBCL. The
large intestine was the most common primary site in
MALT, thus, eleven cases of MALT occurred in the rec-
tum (11/61, 18.0%). Multiple intestinal involvements
such as multicentric involvement were more frequent in
MCL (57.9%), and the pattern of intestinal involvement
in MCL was peculiar. Thus, multi-centric involvement
through entire colon like intestinal polyposis was fre-
quently found in colonoscopy.
Treatments and outcomes
Chemotherapy was the predominant treatment in
patients with primary intestinal NHL regardless of the
involved site. Thus, the majority of patients received
chemotherapy as a curative treatment (n = 521, 89.7%,
Table 4). Various chemotherapy regimens were used,
Table 2 Comparison of clinical features based on primary site of involvement
Characteristics Total cases
(n = 581)
Small
intestine
(n = 162)
Ileocecal
region
(n = 231)
Large
intestine
(n = 125)
Multiple intestinal
involvement
(n = 63)
P value
Age (years) ≤ 60 356 (61.3) 100 (61.7) 146 (63.2) 77 (61.6) 33 (52.4) 0.479
> 60 225 (38.7) 62 (38.3) 85 (36.8) 48 (38.4) 30 (47.6)
Sex Male 367 (63.2) 108 (66.7) 146 (63.2) 73 (58.4) 40 (63.5) 0.557
Female 214 (36.8) 54 (33.3) 85 (36.8) 52 (41.6) 23 (36.5)
Performance status ECOG 0/1 490 (84.3) 135 (83.9) 197 (85.3) 104 (83.2) 54 (85.7) 0.942
ECOG ≥ 2 90 (15.5) 26 (16.0) 34 (14.7) 21 (16.8) 9 (14.3)
Missing 1 (0.2) 1 (0.1)
Serum LDH level Normal 355 (61.1) 92 (56.8) 152 (65.8) 77 (61.6) 34 (54.0) 0.086
Increased 210 (36.1) 67 (41.4) 71 (30.7) 43 (34.4) 29 (46.0)
Missing 16 (2.8) 3 (1.8) 8 (3.5) 5 (4.0)
B symptoms Absent 459 (79.0) 125 (77.2) 185 (80.1) 103 (82.4) 46 (73.0) 0.441
Present 120 (20.7) 36 (22.2) 45 (19.5) 22 (17.6) 17 (27.0)
Missing 2 (0.3) 1 (0.6) 1 (0.4)
Intestinal symptoms Obstruction 96 (16.5) 25 (15.4) 47 (20.3) 14 (11.2) 10 (15.9) 0.267
Bleeding 13 (2.2) 2 (1.2) 8 (3.5) 3 (2.4) 0 (0.0)
Perforation 25 (4.3) 8 (4.9) 13 (5.6) 3 (2.4) 1 (1.6)
Extranodal
involvement
< 2 417 (71.8) 105 (64.8) 179 (77.5) 103 (82.4) 30 (47.6) < 0.001
≥ 2 155 (26.7) 55 (34.0) 47 (20.3) 21 (16.8) 32 (50.8)
Missing 9 (1.5) 2 (1.2) 5 (2.2) 1 (1.0) 1 (1.6)
IPI L/LI 277/151
(75.4)
76/40 (71.6) 129/48 (76.6) 59/38 (77.6) 13/25 (60.3) < 0.001
HI/H 87/53 (22.4) 24/20 (27.2) 33/15 (20.8) 16/8 (19.2) 14/10 (38.1)
Missing 13 (2.2) 2 (1.2) 6 (2.6) 4 (3.2) 1 (1.6)
Lugano stage I/II 139/264
(71.1)
37/73 (67.9) 54/126 (77.9) 43/54 (77.6) 5/21 (41.3) < 0.001
IV 168 (28.9) 52 (32.1) 51 (22.1) 28 (22.4) 37 (58.7)
BM invasion Absent 494 (85.0) 131 (80.9) 199 (86.1) 111 (88.8) 53 (84.1) 0.300
Present 43 (7.4) 17 (10.5) 13 (5.6) 6 (4.8) 7 (11.1)
ND 44 (7.6) 14 (8.6) 19 (8.2) 8 (6.4) 3 (4.8)
Immunophenotype B-cell 504 (86.7) 131 (80.9) 221 (95.7) 106 (84.8) 46 (73.0) < 0.001
T-cell 77 (13.3) 31 (19.1) 10 (4.3) 19 (15.2) 17 (27.0)
ECOG: Eastern Cooperative Oncology Group; LDH: lactate dehydrogenase; IPI: International Prognostic Index; L: low; LI: low-intermediate; HI: high-intermediate; H:
high; BM: bone marrow; ND: not done.
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men for lymphoma, therefore, comparisons of outcomes
based on chemotherapy regimens were not performed.
Surgical resection was performed in 289 patients (49.7%)
for diagnostic and/or therapeutic purposes as mentioned
earlier. Among patients diagnosed by colonoscopy, some
patients underwent surgery to remove primary mass of
intestine. The ileocecal region was the most common
site of surgery (64.1%). Radiotherapy was used less fre-
quently than chemotherapy and surgery. However,
radiotherapy was used frequently in patients with
MALT (n = 13, 21.3%) compared to other subtypes,
while approximately half of all patients with MALT
received chemotherapy due to indolent clinical courses
(n = 30, 49.2%, Table 5). The overall response rates of
DLBCL, BL and MCL were greater than 80% while
Table 3 Comparison of clinical features based on histological subtype
Characteristics DLBCL
No. (%)
MALT
No. (%)
BL
No. (%)
MCL
No. (%)
FL
No. (%)
PTCL-U
No. (%)
EATL
No. (%)
ENKTL
No. (%)
P value
Number of cases 386 61 31 19 7 34 25 18
Median age (range) 56 (15-92) 55 (15-80) 47 (15-78) 60 (42-78) 52 (39-81) 49 (15-78) 51 (23-75) 47 (32-72) 0.002
Age > 60, % 160 (41.5) 22 (36.1) 7 (22.6) 10 (52.6) 3 (42.9) 11 (32.4) 7 (28.0) 5 (27.8) 0.246
Male, % 240 (62.2) 32 (52.5) 25 (80.6) 13 (68.4) 4 (57.1) 24 (70.6) 17 (68.0) 12 (66.7) 0.273
Performance status ≥ 2, % 60 (15.6) 6 (9.8) 5 (16.1) 0 (0.0) 1 (14.3) 9 (26.5) 6 (24.0) 3 (16.7) 0.218
Lugano stage IV, % 94 (24.4) 7 (11.5) 17 (54.8) 15 (78.9) 3 (42.9) 15 (44.1) 8 (32.0) 9 (50.0) < 0.001
Increased serum LDH, % 150 (39.9) 5 (8.5) 23 (76.7) 4 (21.1) 1 (14.3) 12 (36.4) 8 (34.8) 7 (38.9) < 0.001
Presence of B symptoms, % 75 (19.5) 7 (11.5) 7 (22.6) 3 (15.8) 1 (14.3) 12 (35.3) 9 (36.0) 6 (35.3) 0.048
Extranodal involvement ≥ 2, % 93 (24.3) 3 (5.4) 18 (58.1) 9 (47.4) 2 (28.6) 10 (29.4) 10 (41.7) 10 (55.6) < 0.001
IPI HI/H, % 93 (24.5) 5 (8.9) 15 (48.4) 7 (36.8) 1 (14.3) 9 (26.5) 6 (26.1) 4 (22.2) 0.008
Bone marrow invasion, % 20 (5.2) 4 (6.6) 7 (22.6) 5 (26.3) 0 (0.0) 3 (8.8) 3 (12.0) 1 (5.6) < 0.001
Intestinal obstruction, % 69 (17.8) 7 (11.5) 6 (19.4) 0 (0.0) 2 (28.5) 4 (11.8) 4 (16.0) 4 (22.2) 0.398
Bleeding, % 8 (2.0) 2 (3.3) 1 (3.2) 0 (0.0) 0 (0.0) 1 (2.9) 1 (4.0) 0 (0.0) 0.964
Perforation, % 19 (4.9) 1 (1.6) 0 (0.0) 0 (0.0) 0 (0.0) 2 (5.9) 3 (12.0) 0 (0.0) 0.194
Small intestine, % 104 (26.9) 14 (23.0) 11 (35.5) 0 (0.0) 2 (28.6) 13 (38.2) 10 (40.0) 8 (44.4) < 0.001
Ileocecal region, % 187 (48.4) 19 (31.1) 9 (29.0) 3 (15.8) 3 (42.9) 7 (20.6) 2 (8.0) 1 (5.6) < 0.001
Large intestine, % 73 (18.9) 21 (34.4) 5 (16.1) 5 (26.3) 2 (28.6) 5 (14.7) 10 (40.0) 4 (22.2) < 0.001
Multiple intestinal lesions, % 22 (5.7) 7 (11.5) 6 (19.4) 11 (57.9) 0 (0.0) 9 (26.5) 3 (12.0) 5 (27.8) < 0.001
LDH: lactate dehydrogenase; IPI: International Prognostic Index; HI: high-intermediate; H: high; DLBCL: diffuse large B-cell lymphoma; MALT: extranodal marginal
zone B-cell lymphoma; BL: Burkitt lymphoma; PTCL-U: peripheral T-cell lymphoma, unspecified; EATL: enteropathy-associated T-cell lymphoma; MCL: mantle cell
lymphoma; ENKTL: extranodal natural killer/T-cell lymphoma; FL: follicular lymphoma
Table 4 Comparison of treatments and outcomes based on primary site
Characteristics Total cases
(n = 581)
Small intestine
(n = 162)
Ileocecal region
(n = 231)
Large intestine
(n = 125)
Multiple intestinal involvement
(n = 63)
Treatment*
Chemotherapy 521 (89.7%) 143 (88.3%) 213 (92.2%) 105 (84.0%) 60 (95.2%)
Surgical resection 289 (49.7%) 74 (45.7%) 148 (64.1%) 49 (39.2%) 18 (28.6%)
Radiotherapy 56 (9.6%) 21 (13.0%) 18 (7.8%) 13 (10.4%) 4 (6.3%)
Response
Complete response 360 (62.0%) 94 (58.0%) 164 (71.0%) 71 (57.0%) 31 (49.0%)
Partial response 62 (10.7%) 16 (9.9%) 16 (6.9%) 19 (15.0%) 11 (18.0%)
Outcome
Relapse or Progression 199 (34.3%) 57 (35.2%) 65 (28.1%) 50 (40.0%) 27 (42.9%)
Dead 152 (26.2%) 44 (27.2%) 47 (20.3%) 36 (28.8%) 25 (39.7%)
Survival
Median OS Not reached Not reached Not reached 140 months 61 months
5-year OS 67% 65% 72% 67% 55%
Median PFS 88 months 55 months 115 months 66 months 28 months
5-year PFS 53% 50% 62% 50% 37%
*Some patients were treated with combined modality such as surgery plus chemotherapy. Thus, the sum of number of each treatment is larger than total
number of patients.
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overall response rate. Consistent with these findings, the
proportion of relapse or progression was higher in
PTCL-U, EATL and ENKTL, and this fact lead to a
higher number of deaths than in B-cell subtypes.
Among B-cell lymphomas, relapse or progression was
more frequent in MCL and FL, even though they
showed a relatively high overall response rate.
Survival and prognostic factors
The 5-year OS and PFS rates of ileocecal NHL were
72% and 62%, respectively, while the small and large
intestines showed similar survival rates (Figure 1). The
5-year OS rate of B-cell lymphoma was significantly bet-
ter than that of T-cell lymphoma (71% versus 28%, P <
0.001). The comparison of OS in all subtypes of B-cell
lymphoma did not show a significant difference (Figure
2A, P = 0.130). However, when the OS of MALT was
compared with that of DLBCL and MCL, the OS of
MALT was significantly better than DLBCL and MCL
(P = 0.021 and 0.001, respectively). There were no sig-
nificant differences of OS among PTCL-U, EATL, and
ENKTL, although the median OS (34.3 months) of
PTCL-U was longer than that of ENKTL (8.6 months)
and EATL (7.0 months, Figure 2B). The PFS of MCL
and FL was shorter than other subtypes of B-cell NHL
(Figure 2C). However, the PFS of three T-cell subtypes
showed similar outcomes (Figure 2D). Patients with
Lugano stage II2 and IV disease had significantly worse
OS than stage I and II1 (Figure 3A). Other parameters
affecting the IPI score, such as age, ECOG performance
status, serum LDH, and the number of extranodal invol-
vements were also significantly associated with OS (data
not shown). Thus, the IPI showed a clear association
with OS (P < 0.001, Figure 3B). Patients who underwent
surgical resection had better OS than patients who did
not undergo surgery (5-year OS rate 77% versus 57%, P
< 0.001). However, the survival benefit associated with
surgical resection was significant only in B-cell lympho-
mas and not in T-cell lymphomas (Figure 3C, D). Multi-
variate analyses with these parameters for OS showed
that age > 60 years, poor performance status, elevated
serum LDH, Lugano stage IV, presence of B symptoms,
and T-cell phenotype were independent predictive indi-
cators for poor OS (Table 6).
Discussion
Primary intestinal NHL accounts for a major proportion
of cases of extranodal lymphoma. Although its prognosis
is poor compared to gastric lymphoma, there are few
studies analyzing the clinical features and survival out-
comes of primary intestinal NHL according to primary
site of involvement and histologic subtype. In this study,
we analyzed data for 581 patients, making ours the lar-
gest sample among studies investigating primary gastro-
intestinal lymphoma. The clinical features of our study
were similar to those described in previous studies, and
revealed that primary intestinal NHL occurs more fre-
quently in male patients and predominantly presents as
a localized disease (Table 7).
The incidence of B-cell lymphoma was much that of
higher than T-cell lymphoma, and DLBCL was the main
Table 5 Comparison of treatments and outcomes based on histologic subtypes
Characteristics DLBCL
No. (%)
MALT
No. (%)
BL
No. (%)
MCL
No. (%)
FL
No. (%)
PTCL-U
No. (%)
EATL
No. (%)
ENKTL
No. (%)
Treatment*
Chemotherapy 368 (95.3) 30 (49.2) 29 (93.5) 19 (100.0) 5 (71.4) 30 (88.2) 23 (92.0) 17 (94.4)
Surgical resection 223 (57.8) 25 (41.0) 9 (29.0) 1 (5.3) 3 (42.9) 9 (26.5) 12 (48.0) 7 (38.9)
Radiotherapy 32 (8.3) 13 (21.3) 2 (6.5) 1 (5.3) 2 (28.6) 4 (11.8) 1 (4.0) 1 (5.6)
Response
Complete response 264 (68.4) 36 (59.0) 22 (71.0) 11 (57.9) 4 (57.1) 11 (32.4) 7 (28.0) 5 (27.8)
Partial response 36 (9.3) 5 (8.2) 5 (16.1) 5 (26.3) 0 (0.0) 4 (11.8) 4 (16.0) 3 (16.7)
Outcome
Relapse or Progression 112 (29.0) 14 (23.0) 11 (35.5) 8 (42.1) 4 (57.1) 19 (55.9) 18 (72.0) 13 (73.2)
Dead 87 (22.5) 8 (13.1) 7 (22.6) 6 (31.6) 2 (28.6) 18 (52.9) 15 (60.0) 9 (50.0)
Survival
Median OS Not reached Not reached Not reached 46 months 54 months 35 months 8.6 months 7 months
5-year OS 72% 88% 76% 39% 42% 23% 35% 45%
Median PFS Not reached 115 months Not reached 31 months 16 months 10 months 4.2 months 4 months
5-year PFS 58% 80% 60% 0% 22% 17% 23% 21%
*Some patients were treated with combined modality such as surgery plus chemotherapy. Thus, the sum of number of each treatment is larger than total
number of patients.
DLBCL: diffuse large B-cell lymphoma; MALT: extranodal marginal zone B-cell lymphoma; BL: Burkitt lymphoma; PTCL-U: peripheral T-cell lymphoma, unspecified;
EATL: enteropathy-associated T-cell lymphoma; MCL: mantle cell lymphoma; ENKTL: extranodal natural killer/T-cell lymphoma; FL: follicular lymphoma
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Page 6 of 12subtype. This is consistent with the observation that the
majority of gastrointestinal tract NHL is of B-cell origin,
including DLBCL and MALT lymphoma [2,3,8,23].
However, the proportion of DLBCL (n = 386, 66.4%)
was significantly higher than MALT (n = 64, 10.6%) in
our study. This is different from gastric lymphoma, in
which MALT lymphoma accounts for approximately
40% of all cases [15,23]. This high frequency of DLBCL
might be associated with the worse prognosis of intest-
inal lymphoma compared to gastric lymphoma
[1,3,15,24]. The relatively higher incidence of T-cell lym-
phoma may be another cause of the poor prognosis for
intestinal NHL. Our study showed the occurrence of
three subtypes of T-cell lymphoma including PTCL-U,
EATL and ENKTL with a frequency of 13.2%. Although
the proportion of T-cell lymphomas varied according to
the type of study and number of patients [5,9,16], our
proportion was comparable to previous studies with a
relatively large number of patients [1,3,4]. Patients with
T-cell lymphomas more frequently presented with
advanced disease and constitutional B symptoms, and
their overall response rate to treatment was inferior to
that of B-cell lymphomas. This resulted in significantly
worse survival outcomes for T-cell lymphoma compared
to B-cell lymphoma in our study, which is consistent
with previous results [7,16]. The comparison of survival
outcomes based on subtypes of NHL demonstrated that
MCL did not show a survival curve plateau. This reflects
MCL has higher risk of relapse resulting in worse OS
and PFS than other subtypes (Figure 2) in consistent
with previous results [25-27]. The 5-year OS of PTCL-U
in our study was inferior to previously reported 5-year
OS of nodal PTCL-U, suggesting a poor prognosis for
intestinal T-cell lymphoma [28].
The ileocecal region was the most common site of
involvement, accounting for approximately 40% of pri-
mary sites in this study (Table 1). However, this region
was mainly affected by B-cell lymphomas (95.7%). The
frequent occurrence of B-cell lymphomas in the ileoce-
cal region was associated with high proportions of
DLBCL (Table 2). T-cell lymphomas were extremely
rare in the ileocecal region (4.3%), while involvement of
the jejunum was more common in T-cell lymphomas
(12.5%) than in B-cell (3.6%). This relatively high inci-
dence of T-cell lymphomas in the small intestine, espe-
cially the jejunum, was also noted in previous studies
[3,4,6]. Like previous studies reporting high proportions
of MALT lymphoma in the duodenum and rectum in
East Asian samples [6], the high proportion of B-cell
lymphoma in the duodenum and rectum in this study
was also associated with frequent occurrence of MALT
lymphoma.
A comparison of survival outcomes based on primary
site of involvement revealed that involvement of the
Figure 1 Comparison of survival curves based on the site of involvement. (A, B) Overall and progression-free survival curves according to
primary site of involvement. Patients with ileocecal region involvement had better survival outcomes than patients with involvement of the
small and large intestines. The outcomes of patients with multiple intestinal involvement were significantly worse (P < 0.01).
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Page 7 of 12ileocecal region was associated with better survival rates
than involvement of the small and large intestine.
Patients with multiple intestinal involvements had the
worst survival outcomes. A previous study reported that
the overall survival of ileocecal lymphoma was similar to
that of gastric lymphoma and superior to that of small
intestinal lymphoma [4]. There are several possible
explanations for the superior survival outcomes of
patients with involvement in the ileocecal region. First,
T-cell lymphoma rarely occurs in the ileocecal region
compared to the small and large intestine. Thus, the
proportion of T-cell lymphoma in our study (4.3%) was
similar to that of a previous study reporting 4% in the
ileocecal region [4]. Second, lymphomas in the ileocecal
region often presented with complications, such as
obstructions requiring surgical intervention. Thus, more
than 50% of patients with lymphoma in the ileocecal
region underwent immediate surgery [1,4,17,29,30]. Our
s t u d ya l s os h o w e dt h a tt h ep e rcentage of patients who
underwent surgery in the ileocecal region (64.1%) was
significantly higher than the percentage of patients who
required surgery in the small and large intestines (45.7%
Figure 2 Comparison of survival curves based on the histologic subtypes. (A, B) Overall and progression-free survival curves according to
subtype of B-cell lymphoma. MALT lymphoma showed better OS than other subtypes, while BL and DLBCL showed similar OS curves to each
other. (C, D) Overall and progression-free survival curves according to subtype of T-cell lymphoma. There were no significant differences among
PTCL-U, EATL, and ENKTL.
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Page 8 of 12and 39.2%, respectively, Table 4). Previous studies
reported that primary surgical treatment had a favour-
able influence on the prognosis of intestinal lymphoma,
especially for localized disease [7,31]. Thus, the fact that
many of our patients received surgery might explain the
better survival of patients with ileocecal lymphoma in
our study as compared to other studies.
The optimal treatment strategy for intestinal lym-
phoma is still unclear. Although conservative treatment
is preferred to surgery in localized gastric lymphomas,
the same is not true for intestinal lymphomas because
surgery in combination with chemotherapy has proven
superior to any other treatment combination [1,5]. In a
previous study, we compared the outcomes of surgery
Figure 3 Comparison of survival curves based on the clinical characteristics. (A) Lugano stage II2 and IV cases had significantly worse OS,
while there were no significant differences in OS between stage I and II1. (B) IPI was significantly associated with OS. (C) In B-cell lymphoma,
patients who underwent surgical resectioning had better OS than patients that did not. (D) Surgical resections failed to lead to survival
differences in T-cell lymphoma.
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Page 9 of 12followed by chemotherapy, and chemotherapy alone in
intestinal DLBCL, and found that surgery followed by
chemotherapy led to better survival outcomes [32]. Con-
sistent with these findings, surgical resection was asso-
ciated with survival benefits in patients with B-cell
lymphoma in the present study (P < 0.001, Figure 3C).
Considering the fact that more than 90% of patients
received chemotherapy, this result may be interpreted to
reflect a survival advantage of surgery plus chemother-
apy. However, the survival benefit was not observed in
patients with T-cell lymphoma (P = 0.460, Figure 3D),
possibly due to the high proportion of Lugano stage IV
cases in our sample. Thus, need for surgery failed to
show independent prognostic value in the multivariate
Table 6 Multivariate analysis of prognostic factors
Characteristics P value Hazard ratio 95% Confidence Interval
Lower limit Upper limit
Age > 60 < 0.001 1.945 1.379 2.743
Performance status ≥ 2 < 0.001 2.072 1.384 3.101
Elevated serum LDH 0.002 1.776 1.233 2.558
Extranodal involvement ≥ 2 0.579 0.892 0.596 1.335
Lugano stage IV 0.001 1.248 1.090 1.429
Multiple intestinal involvement 0.357 1.076 0.920 1.259
Immunophenotype T-cell < 0.001 3.645 2.454 5.416
B symptoms 0.028 1.530 1.046 2.237
Surgical resection not done 0.281 1.235 0.842 1.811
Table 7 Summary of published results of prospective and retrospective studies
References Study type Time
period
Nationality number Location M/F B/T
cell
Stage I/II vs.
III/IV
B-cell T-cell
d’Amore et al
[1]
Retrospective 1983-1991 Denmark 109 SI/LI 76/33 93/16 56 vs. 48 High grade (51) PTCL (10)
Intermediate grade
(18)
ALCL (6)
Unknown (3) Low grade (21)
Koch et al [4] Retrospective 1992-1996 Germany 58 SI/LI 40/18 48/10 52 vs. 6 High grade (39) T-cell (10)
Low grade (4)
BL/LBL (5)
Kohno et al
[6]
Retrospective 1981-2000 Japan 143 SI/LI 109/34 122/21 Not described Large cell (84), BL
(16)
PTCL (15)
MALT (10), MCL (7) ENKTL (2)
FL (4) ALCL (2)
Daum et al
[16]
Prospective 1995-1999 Germany 56 SI/LI 25/31 21/35 42 vs. 14 DLBCL (18) EATL (28)
MALT (2), FL (1) Unknown
(7)
Yin et al [12] Retrospective 1996-2005 China 34 SI 22/12 27/7 22 vs. 12 DLBCL (24) Unknown
(7)
MALT (3)
Kako et al [10] Retrospective 1990-2007 Japan 23 SI 16/7 20/3 11 vs. 12 DLBCL (15), FL (1) EATL (2)
MCL (1), MALT (2) ALCL (1)
Unknown (1)
Li et al [9] Retrospective 1992-2003 China 40 SI/LI 26/14 38/2 28 vs. 12 DLBCL (17) PTCL (1)
MALT (20) Unknown
(1)
Unknown (1)
Wong et al [8] Retrospective 1989-1999 Singapore 14 LI 13/1 14/0 5 vs. 9 DLBCL (8), MCL (4)
BL (2)
SI: small intestine; LI: large intestine; DLBCL: diffuse large B-cell lymphoma; MALT: extranodal marginal zone B-cell lymphoma; BL: Burkitt lymphoma; PTCL-U:
peripheral T-cell lymphoma, unspecified; EATL: enteropathy-associated T-cell lymphoma; MCL: mantle cell lymphoma; ENKTL: extranodal natural killer/T-cell
lymphoma; FL: follicular lymphoma; LBL: lymphoblastic lymphoma.
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Page 10 of 12analysis for OS (Table 6). The results of our multivariate
analysis demonstrated that age, performance status,
serum LDH, Lugano stage, B symptoms, and T-cell
immunophenotype were all independently prognostic
for OS in patients with intestinal NHL.
Although this is the largest series of primary intestinal
NHL, our study has some limitations. First, patients
included in this analysis were not consecutively diag-
nosed because of its retrospective study in nature. Sec-
ond, we could not provide the results of PET/CT scan
because PET/CT scan was not widely used before 2006
in Korea.
Conclusions
In summary, we determined clinical features and out-
comes of patients with primary intestinal NHL. The sur-
vival of patients with ileocecal region involvement was
better than that of patients with involvement at other
sites, which might be related to histologic distribution,
the proportion of tumor stage, and need for surgical
resection. Factors associated with the IPI score and
T-cell immunophenotype were shown to be prognostic
in this disease entity. Surgical resection may provide sur-
vival benefits to patients with localized B-cell intestinal
NHL.
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